CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors.
CUX1
PanNET
apoptosis
chemotherapy
neuroendocrine
pancreas
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Jul 2020
19 Jul 2020
Historique:
received:
31
05
2020
revised:
09
07
2020
accepted:
16
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Recently, we identified the homeodomain transcription factor Cut homeobox 1 (CUX1) as mediator of tumour de-differentiation and metastatic behaviour in human insulinoma patients. In insulinomas, CUX1 enhanced tumour progression by stimulating proliferation and angiogenesis in vitro and in vivo. In patients with non-functional pancreatic neuroendocrine tumours (PanNET), however, the impact of CUX1 remains to be elucidated. Here, we analysed CUX1 expression in two large independent cohorts (
Identifiants
pubmed: 32707646
pii: cancers12071957
doi: 10.3390/cancers12071957
pmc: PMC7409270
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : Mi 710/10-1
Références
Gut. 2010 Aug;59(8):1101-10
pubmed: 20442202
PLoS One. 2015 Dec 02;10(12):e0143822
pubmed: 26630134
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Br J Cancer. 2015 Feb 3;112(3):523-31
pubmed: 25584486
Ann Oncol. 2008 Oct;19(10):1727-33
pubmed: 18515795
Expert Opin Ther Targets. 2015 Jan;19(1):113-27
pubmed: 25256701
Virchows Arch. 2007 Oct;451(4):757-62
pubmed: 17674042
Nat Cell Biol. 2001 Jan;3(1):1-7
pubmed: 11146619
J Clin Invest. 2015 Jul 1;125(7):2707-20
pubmed: 26075823
Oncol Rep. 2005 May;13(5):937-41
pubmed: 15809761
Endocr Pathol. 2016 Jun;27(2):162-70
pubmed: 26936845
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Annu Rev Biochem. 2006;75:189-210
pubmed: 16756490
Cancer Cell. 2005 Jun;7(6):521-32
pubmed: 15950902
Genes Dev. 1995 Jan 1;9(1):15-30
pubmed: 7828849
Gastroenterology. 2014 Feb;146(2):453-60.e5
pubmed: 24148618
Endocr Relat Cancer. 2008 Dec;15(4):1083-97
pubmed: 18603570
Cancer. 2011 Aug 1;117(15):3332-41
pubmed: 21246527
Nat Rev Cancer. 2014 Oct;14(10):673-82
pubmed: 25190083
Anticancer Res. 2003 Mar-Apr;23(2B):1333-41
pubmed: 12820391
Gene. 2012 Apr 10;497(1):18-26
pubmed: 22306263
Neuroendocrinology. 2014;100(1):35-44
pubmed: 25012122
Clin Gastroenterol Hepatol. 2008 Jul;6(7):820-7
pubmed: 18547872
J Natl Cancer Inst. 2012 May 16;104(10):764-77
pubmed: 22525418
Pancreas. 2017 Nov/Dec;46(10):1354-1358
pubmed: 28984786
J Clin Oncol. 2011 Jun 10;29(17):2372-7
pubmed: 21555696
Virchows Arch. 2006 Oct;449(4):395-401
pubmed: 16967267
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
Clin Cancer Res. 2019 Nov 15;25(22):6692-6699
pubmed: 31375514
Neuroendocrinology. 2017;104(2):170-182
pubmed: 27078712
Pathologe. 2010 Sep;31(5):353-4
pubmed: 20809402
Neuroendocrinology. 2018;107(4):315-323
pubmed: 30025389
Exp Cell Res. 2012 Jul 1;318(11):1213-20
pubmed: 22406265
J Mol Neurosci. 2019 Dec;69(4):527-537
pubmed: 31377983
Endocr Relat Cancer. 2014;21(6):879-90
pubmed: 25248790
Neuroendocrinology. 2012;96(3):173-87
pubmed: 22538498
Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47
pubmed: 2424168
Eur J Cancer. 2015 Jul;51(10):1253-62
pubmed: 25935542
Adv Med Sci. 2016 Mar;61(1):147-53
pubmed: 26774266
Nature. 1985 May 9-15;315(6015):115-22
pubmed: 2986015
Mod Pathol. 2010 Jun;23(6):824-33
pubmed: 20305616
Nature. 1997 Nov 13;390(6656):180-4
pubmed: 9367156
Blood. 2018 Jun 14;131(24):2682-2697
pubmed: 29592892